scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1032129720 |
P356 | DOI | 10.1038/MODPATHOL.2015.98 |
P698 | PubMed publication ID | 26449765 |
P50 | author | Andrea Sartore-Bianchi | Q28321693 |
Salvatore Siena | Q28321703 | ||
Giuseppe Tonini | Q37838300 | ||
Silvio Marco Veronese | Q39051644 | ||
Roberto Labianca | Q39950156 | ||
Silvia Marsoni | Q42882462 | ||
Fortunato Ciardiello | Q43184447 | ||
Fotios Loupakis | Q46107172 | ||
Sara Lonardi | Q50876272 | ||
Vittorina Zagonel | Q56925944 | ||
Emanuele Valtorta | Q57018578 | ||
Cosimo Martino | Q61307821 | ||
Francesco Leone | Q88197017 | ||
Massimo Rugge | Q89598250 | ||
Patrizia Racca | Q115139909 | ||
Katia Bencardino | Q117279618 | ||
Marcello Gambacorta | Q117804625 | ||
Calogero Lauricella | Q117805144 | ||
P2093 | author name string | Carmine Pinto | |
Giuseppe Aprile | |||
Giuseppe Viale | |||
Mauro Risio | |||
Mauro Truini | |||
Carlo Garufi | |||
Johannes Noe | |||
Stefania Mosconi | |||
Barbara Frau | |||
Claudio Graiff | |||
Frédérique Penaullt-Llorca | |||
Walter Grigioni | |||
P2860 | cites work | Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? | Q30856729 | ||
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics | Q33601653 | ||
HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression | Q33690070 | ||
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q33862786 | ||
Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas | Q34029360 | ||
The HER-2/neu oncogene in tumors of the gastrointestinal tract | Q34311106 | ||
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer | Q34344198 | ||
HER2/neu testing in primary colorectal carcinoma | Q34499615 | ||
Significance of human epidermal growth factor receptor 2 expression in colorectal cancer | Q34585338 | ||
HER2: biology, detection, and clinical implications | Q35622862 | ||
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis | Q37251780 | ||
Expression of HER2 in colorectal cancer does not correlate with prognosis | Q37329191 | ||
Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. | Q38087507 | ||
KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. | Q39861972 | ||
HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. | Q40291966 | ||
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. | Q41735415 | ||
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing | Q42431264 | ||
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial | Q45217739 | ||
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study | Q47604705 | ||
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. | Q54402875 | ||
Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. | Q54660628 | ||
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma | Q80227762 | ||
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system | Q81299205 | ||
Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer | Q81711846 | ||
Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system | Q82049151 | ||
P433 | issue | 11 | |
P921 | main subject | colorectal cancer | Q188874 |
colorectal carcinoma | Q25493920 | ||
P304 | page(s) | 1481-1491 | |
P577 | publication date | 2015-10-09 | |
P1433 | published in | Modern Pathology | Q15724578 |
P1476 | title | Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | |
P478 | volume | 28 |
Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
Q38827897 | Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory |
Q54980136 | Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. |
Q64086039 | Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis |
Q54849840 | Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. |
Q92838804 | Correlation of HER2 and FOXM1 in human colorectal carcinoma and its clinical significance |
Q92256962 | Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC) |
Q91830988 | Current and emerging biomarkers in metastatic colorectal cancer |
Q38787244 | Current and future biomarkers in the treatment of colorectal cancer. |
Q39172118 | Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie |
Q39245971 | Downregulation of ALDOB is associated with poor prognosis of patients with gastric cancer |
Q57183898 | Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status |
Q27853380 | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial |
Q90392916 | Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab |
Q37708897 | HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives |
Q39120488 | HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin |
Q92885759 | HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer |
Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
Q89868898 | HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China |
Q36671427 | HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials |
Q90593024 | HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features |
Q59794745 | Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream |
Q50037194 | Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: A report of two instructive cases |
Q58695677 | Multi-Spectral Fluorescence Imaging of Colon Dysplasia InVivo Using a Multi-Spectral Endoscopy System |
Q50089419 | Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. |
Q57739115 | Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives |
Q36432094 | Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer |
Q38794338 | Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications |
Q92912017 | Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal |
Q60960810 | Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases |
Q92280751 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study |
Q39223563 | Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. |
Q64903410 | Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy. |
Q90513170 | Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer |
Q40970786 | Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer. |
Q39045763 | Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer |
Q57162471 | RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine |
Q41105389 | Recent developments in the treatment of metastatic colorectal cancer. |
Q55088555 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. |
Q91291948 | Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients |
Q30315224 | Targeting HER2: precision oncology for colorectal cancer |
Q54962247 | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. |
Q64065309 | The landscape of d16HER2 splice variant expression across HER2-positive cancers |
Q36102672 | Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment. |
Q64262617 | Update on systemic therapy for colorectal cancer: biologics take sides |
Search more.